CLEVELAND, OH / ACCESSWIRE / November 10, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the appointment of Peter
NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1FDA Expands the Scope of the Company's SubmissionAccelerates Path Toward Immunotherapy for Glioblastoma (Brain Cancer)CLEVELAND